Effect of Intestinal Levodopa-Carbidopa Infusion on Pharyngeal Dysphagia: Results from a Retrospective Pilot Study in Patients with Parkinson’s Disease
Parkinson's Disease · 11.03.2020 · 2020 · 1-6
DOI: 10.1155/2020/4260501 ↗Kurz gefasst
Fachartikel in der Zeitschrift Parkinson's Disease, erschienen am 11.03.2020. Verfasst von Bendix Labeit und 5 weiteren Autor:innen. Beteiligte Einrichtung: University Hospital Muenster, Department of Neurology with Institute for Translational Neurology, Albert-Schweitzer-Campus 1; Gebäude A1, Münster 481…. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Muenster.
Themen: Dysphagie
Abstract (Originalsprache)
Background
Pharyngeal dysphagia is a common symptom of Parkinson’s disease (PD) leading to severe complications. PD-related pharyngeal dysphagia (PDrPD) may significantly improve in up to half of patients following acute oral levodopa challenge.
Objective
The aim of this study was to investigate the effects of levodopa-carbidopa intestinal gel (LCIG) on PDrPD.
Methods
Forty-five PD patients under LCIG treatment were available for retrospective analysis. In all patients with PDrPD who underwent flexible endoscopic evaluation of swallowing (FEES) in the clinical “on-state” both before and after implementation of LCIG treatment, FEES videos were systematically reassessed. PDrPD was characterized using a PD-specific FEES score evaluating premature bolus spillage, penetration/aspiration, and pharyngeal residue. Further, the duration of white-out was assessed, as a parameter for pharyngeal bradykinesia.
Results
Eleven patients with PDrPD (mean age 74.6 ± 4.4 years; mean Hoehn and Yahr stage 3.8 ± 0.6) received FEES both before and after the onset of LCIG treatment. The mean swallowing score improved from 14.9 ± 7.3 to 13.0 ± 6.9 after implementation of LCIG; however, this difference was not significant ( p = 0.312 ). Premature bolus spillage decreased significantly ( p = 0.002 ) from 5.4 ± 1.1 to 3.6 ± 1.0, and white-out duration decreased significantly ( p = 0.002 ) from 984 ± 228 ms to 699 ± 131 ms after implementation of LCIG.
Conclusions
LCIG may affect PDrPD and reduce premature bolus spillage and pharyngeal bradykinesia. Future studies with larger sample sizes are required to follow-up on these pilot results and identify which factors predict a good response of PDrPD to LCIG treatment.
Autor:innen und Institutionen
- University Hospital Muenster, Department of Neurology with Institute for Translational Neurology, Albert-Schweitzer-Campus 1; Gebäude A1, Münster 48149, Germany.
- Institute of Biomagnetism and Biosignalanalysis, University Hospital Muenster, University of Muenster, Malmedyweg 15, Münster 48149, Germany.
ORCID-Profile: Bendix Labeit
Förderung
- University of Muenster
Zitieren
APA
Labeit, B., Claus, I., Muhle, P., Suntrup-Krueger, S., Dziewas, R., & Warnecke, T. (2020). Effect of Intestinal Levodopa-Carbidopa Infusion on Pharyngeal Dysphagia: Results from a Retrospective Pilot Study in Patients with Parkinson’s Disease. Parkinson's Disease, 2020, 1-6. https://doi.org/10.1155/2020/4260501
Vancouver
Labeit B, Claus I, Muhle P, Suntrup-Krueger S, Dziewas R, Warnecke T. Effect of Intestinal Levodopa-Carbidopa Infusion on Pharyngeal Dysphagia: Results from a Retrospective Pilot Study in Patients with Parkinson’s Disease. Parkinson's Disease. 2020;2020:1-6. doi:10.1155/2020/4260501
BibTeX
@article{Labeit2020,
author = {Labeit, Bendix and Claus, Inga and Muhle, Paul and Suntrup-Krueger, Sonja and Dziewas, Rainer and Warnecke, Tobias},
title = {Effect of Intestinal Levodopa-Carbidopa Infusion on Pharyngeal Dysphagia: Results from a Retrospective Pilot Study in Patients with Parkinson’s Disease},
journal = {Parkinson's Disease},
year = {2020},
volume = {2020},
pages = {1--6},
doi = {10.1155/2020/4260501}
}
EUVIMED